Pfizer in talks to merge off-patent drugs business with Mylan -source


FILE PHOTO: The logo of U.S. pharmaceutical corporation Pfizer Inc. is seen at a branch in Zurich, Switzerland October 2, 2018. REUTERS/Arnd Wiegmann

(Reuters) – Pfizer Inc (PFE.N) is in talks to merge its off-patent drugs business with Mylan NV (MYL.O) in a stock deal, according to a source familiar with the matter.

Mylan shareholders would receive a little more than 40% of the newly formed entity, with Pfizer shareholders receiving the remainder, the person said, adding that Pfizer would also get about $12 billion in proceeds from a new sale of debt.

Separation of Pfizer’s off-patent business would be a tax-free spin-off, the person added.

Last year, Pfizer said it was planning to reorganize into three units, separating its consumer healthcare business.

The restructuring will allow the company to evaluate its businesses better and could result in selling or spinning off its off-patent drugs, Wall Street analysts earlier said.

The Wall Street Journal first reported about the talks between the companies on Saturday.

Pfizer and Mylan did not immediately respond to requests for comment.

Reporting by Maria Ponnezhath in Bengaluru and Gregory Roumeliotis in New York; Editing by Mark Potter and Paul Simao

Products You May Like

Articles You May Like

British Airways cancels 11% of flights in summer holiday peak
Tragedy as another child dies in US after being left in hot car for hours
These 30 Secrets About Stranger Things Will Turn Your World Upside Down
15 Of The Best Slip-On Shoes For Men That Can Upgrade Any Summer Outfit (2022 Edition)
Texas Migrant deaths: Truck driver was pretending to be survivor when arrested

Leave a Reply

Your email address will not be published.